CQP(SZ:000950)2024-07-08 11:44Financial Performance - The company's estimated net profit attributable to shareholders for the reporting period is projected to be between 220 million and 260 million yuan, representing a year-on-year decline of 49.38% to 57.17% from 513.66 million yuan in the same period last year[10]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 200 million and 240 million yuan, a decrease of 49.33% to 57.78% compared to 473.67 million yuan in the previous year[10]. - The basic earnings per share are projected to be between 0.13 yuan and 0.15 yuan, down from 0.29 yuan per share in the same period last year[10]. Business Strategy - The company is focusing on the development of segmented businesses such as medical devices, traditional Chinese medicine health products, and third-party reserves, alongside its core pharmaceutical sales[10]. - The company emphasizes digital construction and R&D investment as part of its strategic planning for the "14th Five-Year Plan"[10]. Market Challenges - The performance decline is primarily attributed to the tightening of industry policies and the expansion of centralized procurement[3][13]. - The gross profit margin has decreased year-on-year due to the impact of volume-based procurement policies[11]. Future Outlook - The specific financial data will be detailed in the company's 2024 semi-annual report, and investors are advised to pay attention to investment risks[11].